17 Dec 2019 07:45
DIRECTOR DISCLOSURE
17 December, 2019
LONDON, Silence Therapeutics plc (LON: SLN) ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, announces that the Company has been notified that David Horn Solomon, the Company's CEO, is subject to a private creditor action in Denmark arising as a result of his time as Managing Partner of Sund Capital, ApS from 2016 - 2018. Whilst this is a personal matter, entirely unrelated to Silence, a bankruptcy motion has been filed against David in Denmark which is due to be heard by the courts in the next few days. David is keeping the Silence Board closely informed on developments in relation to this matter and is confident that in time he can meet his financial obligations. David remains CEO of Silence.
Enquiries:
Silence Therapeutics plc Iain Ross, Chairman
| Tel: +44 (0)20 3457 6900 |
Peel Hunt LLP (Nominated Adviser and Broker) James Steel/Oliver Jackson
| Tel: +44 (0)20 7418 8900 |
European IR Consilium Strategic Communications Mary-Jane Elliott/Chris Welsh/Angela Gray silencetherapeutics@consilium-comms.com
| Tel: +44 (0) 20 3709 5700 |
US IR Westwicke Partners Peter Vozzo peter.vozzo@westwicke.com
| Tel: +1 (443) 213-0505 |
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural
mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using
its enabling delivery systems, it has achieved an additional level of specificity by delivering its
therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and
delivery systems are designed to improve the stability of our molecules and enhance effective delivery
to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.
For more information, please visit: https://www.silence-therapeutics.com/
SLN.L (SLN)